← All trials
NCT06021990
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2023
- Primary completion
- Sep 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Sep 1, 2023
- Last posted
- Oct 3, 2023
- Enrollment
- 162
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lady Reading Hospital, PakistanLead sponsor
- Lady Reading Hospital, PakistanReponsible party - principal investigator
- Lady Reading Hospital, PakistanStudy chair
- Lady Reading Hospital, PakistanOfficial
- Lady Reading Hospital, PakistanSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.